Why Are We Still Talking about Ivermectin? Editorial Note on Stone et al. Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment.Published in:2022By:Pincus, Seth H.Publication type:Editorial
Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours.Published in:Biologics, 2022, v. 2, n. 3, p. 196, doi. 10.3390/biologics2030015By:Stone, Jaqueline C.;Ndarukwa, Pisirai;Scheim, David E.;Dancis, Barry M.;Dancis, Jerome;Gill, Martin G.;Aldous, ColleenPublication type:Article
Biosimilars: Harmonizing the Approval Guidelines.Published in:Biologics, 2022, v. 2, n. 3, p. 171, doi. 10.3390/biologics2030014By:Niazi, Sarfaraz K.Publication type:Article
Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes.Published in:2022By:Chavda, Vivek P.;Chhabria, Mahesh T.;Apostolopoulos, VassoPublication type:Editorial